Title:
ＲＡＦ阻害剤及びＥＲＫ阻害剤を含む治療用組合せ
Document Type and Number:
Japanese Patent JP7114575
Kind Code:
B2
Abstract:
The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.
Inventors:
Caponiro, Giordano
Mayer, Matthew John
Cook, veselina
Stuart, Dallin
Mayer, Matthew John
Cook, veselina
Stuart, Dallin
Application Number:
JP2019515203A
Publication Date:
August 08, 2022
Filing Date:
September 18, 2017
Export Citation:
Assignee:
Novartis Age
International Classes:
A61K31/5377; A61K31/4965; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| JP2016517417A |
Foreign References:
| WO2015066188A1 | ||||
| WO2016115376A1 | ||||
| WO2014151616A1 |
Other References:
Expert Opin. Pharmacother.,15(5),2014年,pp.589-592
Nature Reviews Drug Discovery,13,2014年,pp.928-942
Nature Reviews Drug Discovery,13,2014年,pp.928-942
Attorney, Agent or Firm:
Hiroshi Kobayashi
Eiji Katayama
Norio Omori
Sayaka Hirakawa
Yasuhito Suzuki
Eiji Katayama
Norio Omori
Sayaka Hirakawa
Yasuhito Suzuki